Lechenie revmatoidnogo artrita:sredstva dlya dostizheniya tseli
- Authors: Olyunin Y.A1
-
Affiliations:
- НИИ ревматологии РАМН, Москва
- Issue: Vol 13, No 9 (2011)
- Pages: 61-65
- Section: Articles
- URL: https://bakhtiniada.ru/2075-1753/article/view/93471
- ID: 93471
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##References
- Smolen J.S., Aletaha D, Bijlsma J.W. et al. T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69 (4): 631–7.
- Smolen J.S., Landew é R, Breedveld F.C. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease - modifying antirheumatic drugs. Ann Rheum Dis 2010; 69 (6): 964–75.
- Saag K.G., Teng G.G., Patkar N.M. et al. American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59 (6): 762–84.
- Caplan L, Wolfe F, Russell A.S., Michaud K. Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol 2007; 34 (4): 696–705.
- Kellner H, Bornholdt K, Hein G. Leflunomide in the treatment of patients with early rheumatoid arthritis – results of a prospective non - interventional study. Clin Rheumatol 2010; 29 (8): 913–20.
- Boers M, Verhoeven A.C., Markusse H.M. et al. Randomised comparison of combined step - down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350 (9074): 309–18.
- Svensson B et al. Low - dose prednisolone in addition to the initial disease - modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and in - creases the remission rate: a two - year randomized trial. Arthritis Rheum 2005; 52 (11): 3360–70.
- Emery P, Breedveld F, van der Heijde D et al. Combination of Methotrexate and Etanercept in Early Rheumatoid Arthritis Trial Group. Two - year clinical and radiographic results with combination etanercept - methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two - year, double - blind, randomized study. Arthritis Rheum 2010; 62 (3): 674–82.
- Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F. et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52 (11): 3381–90.
- Klarenbeek N.B., Güler-Yüksel M, van der Kooij S.M. et al. The impact of four dynamic, goal steered treatment strategies on the 5 - year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 2011; 70 (6): 1039–46.
- Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single - blind randomised controlled trial. Lancet 2004; 17–23, 364 (9430): 263–9.
- Cantini F, Nannini C, Niccoli L. Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Open Access Rheumatology: Research and Reviews 2009; 1: 163–78.
- Kalden J.R., Nüsslein H.G., Wollenhaupt J et al. Combination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis: safety and efficacy in an open - label clinical trial. Clin Exp Rheumatol 2008; 26 (5): 834–40.
- De Stefano R, Frati E, Nargi F et al. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide - anti - TNF - alpha versus methotrexate - anti - TNF - alpha. Clin Rheumatol 2010; 29 (5): 517–24.
- Strangfeld A, Hierse F, Kekow J et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 2009; 68 (12): 1856–62.
- Wendler J, Soerensen H, Tony H et al. Effectiveness and safety of rituximab (RTX) - monotherapy compared to RTX-combination therapy with methotrexate (MTX) or leflunomide (LEF) in the German RTX treatment of active rheumatoid arthritis (RA) in daily practice trial. Ann Rheum Dis 2009; 68 (Suppl. 3): 76.
- Насонов Е.Л., Лукина Г.В., Сигидин Я.А. Комбинированная терапия ритуксимабом и лефлуномидом при ревматоидном артрите (предварительные результаты российского регистра АРБИТР). Научно - практическая ревматология. 2011; 1: 16–20.
- Gabay C et al. Effectiveness of different DMARD co - therapies in rituximab - treated rheumatoid arthritis (RA) patients – results of a one - year follow up study from the CERRERA collaboration Ann Rheum Dis 2010; 69 (Suppl. 3): 68.
Supplementary files
